Poster Additional Sessions track
Poster Session 1 - Meeting Unmet Medical Needs in Rare Diseases: Are Patient Preferences and Incentives Aligned with Policy?
Tue, Mar 18, 2025 · 12:15–1:15 PM CET Shanghai 1-2 Room, Congress Center Basel
About this session
This session explores the critical intersection of patient preferences, incentives, and policy in addressing unmet medical needs in rare diseases.
Through rapid poster presentations, authors will delve into key issues and insights, including:
- Stakeholders' Perspectives on Defining Unmet Medical Need in European Pharmaceutical Legislation
- Stakeholders' Perspectives on Incentive Measures for Unmet Medical Needs in the Reform of the European Pharmaceutical Legislation
- Understanding Treatment Preferences in Duchenne Muscular Dystrophy: Quantitative Insights from Patients and Caregivers
- Integrating Patient Preferences and Unmet Health-Related Needs: A Holistic Approach to Advance Patient-Centred Healthcare
- A Targeted Review of the Challenges and Strategies for Submitting Patient-Generated Evidence to Health Technology Assessment Agencies
- How Pharmacovigilance is Incorporating the Concept of Patient Centricity – An Industry Leading Approach
The session will conclude with an engaging Q&A, offering attendees the opportunity to discuss these topics further with the presenters and explore actionable strategies for aligning patient needs and policy frameworks.
Programme:
- 1. Stakeholders' Perspectives on Defining Unmet Medical Need in European Pharmaceutical Legislation — Zilke Claessens
- 2. Stakeholders' Perspectives on Incentive Measures for Unmet Medical Needs in the Reform of the European Pharmaceutical Legislation — Io Wens
- 3. Understanding Treatment Preferences in Duchenne Muscular Dystrophy: Quantitative Insights from Patients and Caregivers — Thomas Desmet
- 4. Integrating patient preferences and unmet health-related needs: A holistic approach to advance patient-centred healthcare — Alice Vanneste
- 5. Opportunities and challenges of patient-submitted evidence into rare diseases HTA — Neil Bertelsen
- 6. How Pharmacovigilance is incorporating the concept of Patient Centricity – An Industry Leading Approach — Linda Smeding
Speakers
-
Chair, Patient and Citizen Involvement in HTA IG · Health Technology Assessment international (HTAi)
Speaker
-
PhD researcher · KU Leuven
Speaker
-
PhD researcher · KU Leuven
Speaker
-
Head of Safety Evaluation and Risk Management Head, Executive Medical Director · GlaxoSmithKline
Speaker
